I saw that as well. The issue is that it is only approved for...

I saw that as well. The issue is that it is only approved for CSME, not for use in AMD patients (which is the primary intention and largest market). To have it approved for patients with AMD would require undergoing the entire approval process again. However, I do believe that there should be no reason for it not to pass a phase one clinical trial if its safety has already been proved in clinical trials for use in CSME patients. It is the efficacy trials (trials two and three) that I worry about. Nonetheless, I think I am sufficiently satisfied to enter into a small position, with additional cash on the sidelines pending updates. A treatment for dry AMD would be a major technological development and there is certainly a huge market (which is growing due to the aging of the population) for the pharmaceutical company that manages to finally develop a successful treatment option for individuals with this disease.